A research team discovers a novel bacterial toxin that causes severe hypotension in infected patients. In vitro studies show the toxin ADP-ribosylates a specific amino acid on Gq alpha subunits, preventing their activation by GPCRs. Patients develop hypotension despite elevated levels of vasopressin, angiotensin II, and endothelin-1. Synthesize the pathophysiological mechanism explaining why multiple vasopressor hormones fail to maintain blood pressure in these patients.
Q2
A 42-year-old woman with metastatic melanoma develops severe colitis while being treated with ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody). Her oncologist must decide whether to continue immunotherapy or treat the colitis with immunosuppression. Tumor analysis shows high PD-L1 expression and BRAF wild-type status. Previous conventional chemotherapy failed. Evaluate the optimal management strategy considering signal transduction implications.
Q3
A 35-year-old man with familial adenomatous polyposis (FAP) undergoes genetic counseling. He has a germline APC mutation and asks about cancer risk for his children. His physician explains that APC normally regulates beta-catenin levels. Evaluate which downstream transcriptional consequence most directly results from loss of functional APC protein in colonic epithelial cells.
Q4
A 58-year-old woman with HER2-positive metastatic breast cancer initially responds to trastuzumab (anti-HER2 antibody) but develops resistance after 18 months. Tumor analysis reveals increased expression of HER3 and continued PI3K/AKT pathway activation despite HER2 blockade. Analyze the mechanism underlying this adaptive resistance.
Q5
A 4-year-old boy presents with recurrent bacterial infections, eczema, and elevated IgE levels. Flow cytometry shows absent expression of Wiskott-Aldrich syndrome protein (WASP) in his leukocytes. His T cells show impaired responses to T-cell receptor stimulation. Analyze the mechanism by which absent WASP impairs T-cell receptor signaling and cellular function.
Q6
A 62-year-old man with metastatic colorectal cancer is being treated with cetuximab, an EGFR inhibitor. Despite initial response, the tumor progresses. Genetic analysis of the resistant tumor reveals a KRAS G12V mutation that was not present in the original tumor. Analyze why this mutation confers resistance to EGFR inhibition.
Q7
A 55-year-old man with chronic lymphocytic leukemia is started on ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor. His oncologist explains that this drug blocks B-cell receptor signaling. Apply your understanding to identify which downstream signaling molecule's activation is most directly inhibited by blocking BTK in B-cell receptor signaling?
Q8
A 28-year-old woman presents with palpitations, tremor, and weight loss. Physical examination reveals exophthalmos, pretibial myxedema, and diffuse thyroid enlargement. Laboratory studies confirm Graves' disease with elevated thyroid hormones and TSH receptor antibodies. The TSH receptor antibodies act as agonists at the TSH receptor on thyroid follicular cells. Apply your knowledge to determine which intracellular signaling cascade is activated by these antibodies to cause excessive thyroid hormone production?
Q9
A 3-year-old boy presents with severe dehydration, chronic watery diarrhea, and failure to thrive. Laboratory studies reveal hypochlorhydria and elevated vasoactive intestinal peptide (VIP) levels. Imaging reveals a pancreatic mass consistent with VIPoma. The excessive VIP secretion causes persistent activation of which signal transduction pathway in intestinal epithelial cells to produce the diarrhea?
Q10
A 45-year-old woman with type 2 diabetes mellitus presents for routine follow-up. Her physician prescribes exenatide, a GLP-1 receptor agonist, to improve glycemic control. The drug increases insulin secretion and decreases glucagon release in a glucose-dependent manner. Through which signal transduction mechanism does GLP-1 receptor activation primarily lead to insulin secretion in pancreatic beta cells?
Signal transduction pathways US Medical PG Practice Questions and MCQs
Question 1: A research team discovers a novel bacterial toxin that causes severe hypotension in infected patients. In vitro studies show the toxin ADP-ribosylates a specific amino acid on Gq alpha subunits, preventing their activation by GPCRs. Patients develop hypotension despite elevated levels of vasopressin, angiotensin II, and endothelin-1. Synthesize the pathophysiological mechanism explaining why multiple vasopressor hormones fail to maintain blood pressure in these patients.
A. The toxin depletes intracellular ATP preventing myosin-actin interaction
B. The toxin prevents receptor binding of vasopressor hormones through allosteric inhibition
C. ADP-ribosylation of Gq prevents PLC activation, blocking IP3-mediated calcium release and vascular smooth muscle contraction (Correct Answer)
D. ADP-ribosylation increases cAMP levels causing smooth muscle relaxation
E. The toxin activates Gi proteins causing excessive vasodilation that overwhelms vasoconstrictor signals
Explanation: ***ADP-ribosylation of Gq prevents PLC activation, blocking IP3-mediated calcium release and vascular smooth muscle contraction***
- Vasopressor hormones like **Vasopressin**, **Angiotensin II**, and **Endothelin-1** signal through **Gq-coupled receptors** to trigger **vascular smooth muscle contraction**.
- By ADP-ribosylating the **Gq alpha subunit**, the toxin inhibits **Phospholipase C (PLC)**, preventing the generation of **IP3 and DAG**, which are essential for releasing **intracellular calcium**.
*The toxin prevents receptor binding of vasopressor hormones through allosteric inhibition*
- The toxin targets the **G-protein (intracellular)** rather than the **extracellular binding site** of the G-protein coupled receptors (GPCRs).
- Since binding still occurs but **signal transduction** is blocked, this describes a post-receptor defect rather than **allosteric inhibition** of the receptor itself.
*The toxin activates Gi proteins causing excessive vasodilation that overwhelms vasoconstrictor signals*
- The prompt explicitly states the toxin modifies the **Gq alpha subunit**, not the **Gi subunit**.
- **Gi protein** activation primarily lowers **cAMP**, whereas the failure of pressors in this case is linked to the lack of **calcium mobilization** via Gq.
*ADP-ribosylation increases cAMP levels causing smooth muscle relaxation*
- Increased **cAMP** (via Gs activation or Gi inhibition) does cause relaxation, but this mechanism is associated with toxins like **Cholera** or **Pertussis**.
- The modification of **Gq** specifically disrupts the **phosphoinositol pathway**, not the **adenylyl cyclase** pathway that regulates cAMP.
*The toxin depletes intracellular ATP preventing myosin-actin interaction*
- ADP-ribosylation is a specific **post-translational modification** using **NAD+** as a substrate, which does not result in systemic **ATP depletion**.
- The failure of contraction is due to a lack of **calcium-calmodulin** activation of **Myosin Light Chain Kinase (MLCK)**, not a lack of energy supply for the motor proteins.
Question 2: A 42-year-old woman with metastatic melanoma develops severe colitis while being treated with ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody). Her oncologist must decide whether to continue immunotherapy or treat the colitis with immunosuppression. Tumor analysis shows high PD-L1 expression and BRAF wild-type status. Previous conventional chemotherapy failed. Evaluate the optimal management strategy considering signal transduction implications.
A. Stop both drugs permanently as immune-related adverse events indicate loss of self-tolerance mechanisms
B. Continue both checkpoint inhibitors as tumor response depends on sustained T-cell receptor co-stimulation blockade
C. Discontinue ipilimumab, continue nivolumab with corticosteroids, as PD-1 pathway blockade may be sufficient given high PD-L1 expression (Correct Answer)
D. Continue both drugs but add TNF-alpha inhibitor to block inflammatory signaling without affecting anti-tumor immunity
E. Stop all immunotherapy and switch to targeted therapy despite BRAF wild-type status
Explanation: ***Discontinue ipilimumab, continue nivolumab with corticosteroids, as PD-1 pathway blockade may be sufficient given high PD-L1 expression***
- Severe colitis is a significant **immune-related adverse event (irAE)**; managing it requires **corticosteroids** to suppress the excessive T-cell response while balancing anti-tumor efficacy.
- In patients with **high PD-L1 expression**, the **PD-1 inhibitor (Nivolumab)** may provide sufficient anti-tumor signal transduction blockade alone, allowing for the discontinuation of the more toxic **anti-CTLA-4** agent.
*Continue both checkpoint inhibitors as tumor response depends on sustained T-cell receptor co-stimulation blockade*
- Sustaining treatment during severe colitis poses a high risk of **colon perforation** and death due to uncontrolled lymphocytic infiltration.
- **CTLA-4** blockade affects the priming phase in lymph nodes, and continuing it during high-grade toxicity is contraindicated by clinical safety guidelines.
*Stop all immunotherapy and switch to targeted therapy despite BRAF wild-type status*
- Targeted therapies like **BRAF and MEK inhibitors** require the **BRAF V600 mutation** to function; they are ineffective in **BRAF wild-type** status.
- Switching to these agents would leave the patient with no effective treatment for the underlying **metastatic melanoma**.
*Continue both drugs but add TNF-alpha inhibitor to block inflammatory signaling without affecting anti-tumor immunity*
- While **TNF-alpha inhibitors** like infliximab are used for refractory colitis, they are typically added only after **corticosteroids** fail to control symptoms.
- Clinical protocols mandate the suspension of the offending agents during **Grade 3/4 toxicity** to prevent further immune-mediated tissue damage.
*Stop both drugs permanently as immune-related adverse events indicate loss of self-tolerance mechanisms*
- Benefit-risk assessment often allows for the resumption of **PD-1 inhibitors** once toxicity resolves, especially if the tumor shows evidence of responding.
- **Permanent discontinuation** of all life-saving immunotherapy may not be necessary if the toxicity is managed and the clinical benefit of the **PD-1 pathway** blockade is high.
Question 3: A 35-year-old man with familial adenomatous polyposis (FAP) undergoes genetic counseling. He has a germline APC mutation and asks about cancer risk for his children. His physician explains that APC normally regulates beta-catenin levels. Evaluate which downstream transcriptional consequence most directly results from loss of functional APC protein in colonic epithelial cells.
A. Increased SMAD-mediated transcription of growth inhibitory genes
B. Decreased TCF/LEF-mediated transcription of cell cycle genes like c-MYC and cyclin D1
C. Increased p53-mediated transcription of pro-apoptotic genes
D. Decreased NF-kB transcriptional activity reducing inflammatory gene expression
E. Constitutive TCF/LEF-mediated transcription of proliferation genes due to nuclear beta-catenin accumulation (Correct Answer)
Explanation: ***Constitutive TCF/LEF-mediated transcription of proliferation genes due to nuclear beta-catenin accumulation***
- In the absence of functional **APC protein**, the destruction complex cannot phosphorylate **beta-catenin**, leading to its accumulation in the cytoplasm and subsequent translocation to the **nucleus**.
- Once in the nucleus, **beta-catenin** acts as a co-activator for **TCF/LEF transcription factors**, leading to persistent expression of oncogenes like **c-MYC** and **cyclin D1**.
*Decreased TCF/LEF-mediated transcription of cell cycle genes like c-MYC and cyclin D1*
- Loss of **APC** leads to an **increase**, rather than a decrease, in the transcriptional activity of TCF/LEF because **beta-catenin** is no longer being degraded.
- This inappropriate activation of the **Wnt signaling pathway** is what drives the formation of colonic adenomas in patients with **FAP**.
*Increased p53-mediated transcription of pro-apoptotic genes*
- **APC** mutations primarily affect the **Wnt/beta-catenin pathway**, whereas **p53** mutations typically occur later in the adenoma-carcinoma sequence.
- Loss of functional APC does not directly increase **p53-mediated apoptosis**; if anything, it provides a selective advantage for cells to bypass growth controls.
*Decreased NF-kB transcriptional activity reducing inflammatory gene expression*
- The **NF-kB pathway** is a separate signaling cascade involved in inflammation and immune response, not the primary mechanism of **APC/beta-catenin** tumorigenesis.
- APC loss specifically targets **proliferation genes** through beta-catenin stabilization, rather than reducing **NF-kB** activity.
*Increased SMAD-mediated transcription of growth inhibitory genes*
- **SMAD proteins** are downstream effectors of the **TGF-beta signaling pathway**, which typically provides growth inhibitory signals in the colon.
- Mutations in the **TGF-beta/SMAD** pathway often occur later in colon cancer progression and are distinct from the early **APC** mutation consequences.
Question 4: A 58-year-old woman with HER2-positive metastatic breast cancer initially responds to trastuzumab (anti-HER2 antibody) but develops resistance after 18 months. Tumor analysis reveals increased expression of HER3 and continued PI3K/AKT pathway activation despite HER2 blockade. Analyze the mechanism underlying this adaptive resistance.
A. HER3 activates p53 pathway bypassing the need for HER2 signaling
B. HER3 directly activates PI3K independent of HER2 through compensatory heterodimerization with other receptors (Correct Answer)
C. HER3 increases expression of drug efflux pumps removing trastuzumab from cells
D. HER3 downregulates HER2 expression eliminating the drug target
E. HER3 blocks trastuzumab binding sites on HER2 through steric hindrance
Explanation: ***HER3 directly activates PI3K independent of HER2 through compensatory heterodimerization with other receptors***
- **HER3** is a potent activator of the **PI3K/AKT pathway** because it contains multiple binding sites for the **p85 subunit of PI3K**, which allows it to maintain signaling when HER2 is blocked.
- Increased **HER3 expression** facilitates the formation of **HER2/HER3 or HER3/RTK heterodimers**, effectively bypassing trastuzumab inhibition to drive tumor cell survival and proliferation.
*HER3 increases expression of drug efflux pumps removing trastuzumab from cells*
- Trastuzumab is a **monoclonal antibody** and is not typically a substrate for **ATP-binding cassette (ABC) transporters** like P-glycoprotein, which handle small molecule drugs.
- Resistance to antibodies usually involves **signaling bypass** or altered receptor recycling rather than classic **multidrug resistance (MDR)** efflux mechanisms.
*HER3 blocks trastuzumab binding sites on HER2 through steric hindrance*
- **Trastuzumab** binds to the **extracellular domain IV** of HER2; there is no evidence that HER3 upregulation physically masks this specific epitope.
- Resistance is biochemical and functional through **downstream signaling restoration**, not a physical blockade of the antibody-receptor docking site.
*HER3 downregulates HER2 expression eliminating the drug target*
- In cases of acquired resistance, **HER2 amplification** and expression generally persist, as the tumor remains dependent on the **HER family signaling network**.
- The scenario explicitly states there is **continued PI3K/AKT activation** despite HER2 blockade, suggesting the target is still present but the pathway is being rerouted via **HER3**.
*HER3 activates p53 pathway bypassing the need for HER2 signaling*
- The **p53 pathway** is a tumor suppressor pathway that induces **apoptosis** or cell cycle arrest, whereas resistance mechanisms select for **oncogenic survival pathways**.
- HER3 upregulation specifically drives **PI3K/AKT signaling**, which actually inhibits apoptosis and counteracts the effects of p53 to promote **cell survival**.
Question 5: A 4-year-old boy presents with recurrent bacterial infections, eczema, and elevated IgE levels. Flow cytometry shows absent expression of Wiskott-Aldrich syndrome protein (WASP) in his leukocytes. His T cells show impaired responses to T-cell receptor stimulation. Analyze the mechanism by which absent WASP impairs T-cell receptor signaling and cellular function.
A. WASP prevents T-cell receptor internalization maintaining surface expression
B. WASP normally inhibits phospholipase C preventing excessive calcium signaling
C. WASP is required for actin polymerization necessary for immune synapse formation and downstream signaling (Correct Answer)
D. WASP activates adenylyl cyclase to produce cAMP for T-cell activation
E. WASP directly phosphorylates CD3 chains to initiate T-cell receptor signaling
Explanation: ***WASP is required for actin polymerization necessary for immune synapse formation and downstream signaling***
- **WASP** functions as an adapter protein that links membrane signaling to the **actin cytoskeleton** by activating the **Arp2/3 complex**.
- Absence of WASP prevents the **cytoskeletal reorganization** required to form a stable **immunological synapse**, which is essential for effective **T-cell receptor (TCR) signaling** and lymphocyte activation.
*WASP normally inhibits phospholipase C preventing excessive calcium signaling*
- **WASP** does not act as an inhibitor of **PLC-gamma**; instead, it is activated downstream of PLC-gamma following TCR stimulation.
- Calcium signaling is actually **diminished** or improperly localized in WASP deficiency due to the failure of the **signalosome** to organize correctly on the actin scaffold.
*WASP directly phosphorylates CD3 chains to initiate T-cell receptor signaling*
- Phosphorylation of **CD3 ITAMs** is performed by **Src-family kinases** like **Lck**, not by cytoskeletal adapter proteins like WASP.
- **WASP** lacks a kinase domain; it serves purely as a **scaffold and regulator** of actin dynamics rather than a primary signaling enzyme.
*WASP activates adenylyl cyclase to produce cAMP for T-cell activation*
- High levels of **cAMP** generally act as an **inhibitory** signal for T-cell activation, whereas WASP is required for stimulatory pathways.
- The activation of **adenylyl cyclase** is mediated by **G-protein coupled receptors**, whereas WASP is recruited by small GTPases like **Cdc42**.
*WASP prevents T-cell receptor internalization maintaining surface expression*
- WASP deficiency typically leads to **increased** turnover and defective transport, but the primary defect is in **actin-mediated mobility** and receptor clustering.
- The hallmark of **Wiskott-Aldrich Syndrome** is not primarily TCR density but the inability to relocate receptors into a functional **central supramolecular activation cluster (cSMAC)**.
Question 6: A 62-year-old man with metastatic colorectal cancer is being treated with cetuximab, an EGFR inhibitor. Despite initial response, the tumor progresses. Genetic analysis of the resistant tumor reveals a KRAS G12V mutation that was not present in the original tumor. Analyze why this mutation confers resistance to EGFR inhibition.
A. KRAS G12V increases drug efflux pumps reducing intracellular cetuximab
B. KRAS G12V increases EGFR expression bypassing the drug effect
C. KRAS G12V mutation causes constitutive activation independent of upstream EGFR signaling (Correct Answer)
D. KRAS G12V mutation activates alternative receptor tyrosine kinases
E. KRAS G12V enhances binding affinity of EGFR for its ligand
Explanation: ***KRAS G12V mutation causes constitutive activation independent of upstream EGFR signaling***
- **KRAS** is a downstream signaling molecule in the **MAPK pathway**; a **G12V mutation** locks the protein in a **constitutive GTP-bound state**, bypasssing the need for **EGFR** activation.
- Because the signaling is active **distal** to the receptor, blocking **EGFR** with **cetuximab** is ineffective as the proliferative signals continue to reach the nucleus.
*KRAS G12V increases EGFR expression bypassing the drug effect*
- Resistance via **KRAS** does not rely on increasing the number of **EGFR** receptors but rather on making the receptor's activity **irrelevant** to cell survival.
- **EGFR overexpression** is a separate mechanism of resistance and does not describe the specific biochemical consequence of a **G12V mutation**.
*KRAS G12V enhances binding affinity of EGFR for its ligand*
- The **KRAS mutation** occurs in an **intracellular GTPase** and does not change the **extracellular binding affinity** of the **EGFR** receptor for its ligands.
- High ligand affinity would still technically be susceptible to **competitive inhibition** by cetuximab, whereas **constitutive KRAS** activity is completely **ligand-independent**.
*KRAS G12V mutation activates alternative receptor tyrosine kinases*
- While **RTK bypass** (like MET or HER2 amplification) is a known resistance mechanism, **KRAS** itself is a **downstream mediator**, not an upstream receptor tyrosine kinase.
- Activating alternative receptors would involve different genetic alterations, whereas **KRAS G12V** specifically targets the **GTPase-mediated** step of the cascade.
*KRAS G12V increases drug efflux pumps reducing intracellular cetuximab*
- **Cetuximab** is a **monoclonal antibody** that targets the **extracellular domain** of EGFR; it does not need to enter the cell to function, making **intracellular efflux pumps** irrelevant.
- Efflux pump resistance (like **MDR1**) typically applies to **small molecule inhibitors** or chemotherapy, not large **biologics** like antibodies.
Question 7: A 55-year-old man with chronic lymphocytic leukemia is started on ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor. His oncologist explains that this drug blocks B-cell receptor signaling. Apply your understanding to identify which downstream signaling molecule's activation is most directly inhibited by blocking BTK in B-cell receptor signaling?
A. Phospholipase A2 leading to decreased arachidonic acid production
B. Adenylyl cyclase leading to decreased cAMP production
C. Phospholipase C-gamma leading to decreased IP3 and DAG production (Correct Answer)
D. PI3-kinase leading to decreased PIP3 production
E. Guanylyl cyclase leading to decreased cGMP production
Explanation: ***Phospholipase C-gamma leading to decreased IP3 and DAG production***
- **BTK** is a vital component of the **B-cell receptor (BCR)** signaling complex that directly phosphorylates and activates **Phospholipase C-gamma (PLCγ2)**.
- This activation is essential for generating **IP3** and **DAG**, which trigger calcium mobilization and **PKC** activation, ultimately driving B-cell survival and proliferation.
*Adenylyl cyclase leading to decreased cAMP production*
- **Adenylyl cyclase** is typically activated by **G-protein coupled receptors (GPCRs)** via Gs proteins, not directly by the **BCR-BTK** pathway.
- Decreased **cAMP** levels are not the primary biochemical consequence of blocking **Bruton tyrosine kinase** signaling.
*Guanylyl cyclase leading to decreased cGMP production*
- **Guanylyl cyclase** converts GTP to **cGMP** in response to nitric oxide or natriuretic peptides, which is unrelated to the **BTK** kinase cascade.
- This signaling pathway is involved in **vasodilation** and fluid balance rather than **B-cell receptor** signal transduction.
*PI3-kinase leading to decreased PIP3 production*
- **PI3-kinase** acts **upstream** of BTK; it produces **PIP3**, which serves as the membrane anchor that recruits BTK via its **PH domain**.
- Inhibiting BTK blocks the signals downstream of PIP3, but it does not prevent **PI3-kinase** from producing PIP3 itself.
*Phospholipase A2 leading to decreased arachidonic acid production*
- **Phospholipase A2** is responsible for releasing **arachidonic acid** from membrane phospholipids, primarily in response to inflammatory stimuli or mechanical stress.
- While important for **eicosanoid synthesis**, it is not a direct downstream effector molecule of the **BTK enzyme** in the BCR signaling pathway.
Question 8: A 28-year-old woman presents with palpitations, tremor, and weight loss. Physical examination reveals exophthalmos, pretibial myxedema, and diffuse thyroid enlargement. Laboratory studies confirm Graves' disease with elevated thyroid hormones and TSH receptor antibodies. The TSH receptor antibodies act as agonists at the TSH receptor on thyroid follicular cells. Apply your knowledge to determine which intracellular signaling cascade is activated by these antibodies to cause excessive thyroid hormone production?
A. Gi protein inhibition of adenylyl cyclase decreasing cAMP
B. Gq-PLC-IP3-Ca2+ pathway increasing thyroglobulin synthesis
C. Gs-adenylyl cyclase-cAMP-PKA pathway increasing iodine uptake and hormone synthesis (Correct Answer)
D. TGF-beta receptor-SMAD pathway regulating gene transcription
E. Receptor tyrosine kinase-RAS-RAF-MEK-ERK pathway
Explanation: ***Gs-adenylyl cyclase-cAMP-PKA pathway increasing iodine uptake and hormone synthesis***
- The **TSH receptor** is a **G-protein coupled receptor (GPCR)**; when thyroid-stimulating immunoglobulins (TSI) bind, they activate the **Gs protein** subunit.
- This activation stimulates **adenylyl cyclase** to increase **intracellular cAMP**, which activates **Protein Kinase A (PKA)** to drive **iodine uptake**, **thyroglobulin iodination**, and hormone release.
*Gq-PLC-IP3-Ca2+ pathway increasing thyroglobulin synthesis*
- While some TSH receptors can couple with the **Gq pathway** at very high concentrations of TSH, it is not the primary pathway for stimulating **thyroid hormone synthesis**.
- The Gq pathway primarily regulates **phospholipid metabolism** and intracellular **calcium release**, whereas the **cAMP pathway** is the hallmark of Graves' disease pathogenesis.
*Receptor tyrosine kinase-RAS-RAF-MEK-ERK pathway*
- This pathway is typically activated by **growth factors** (e.g., insulin, IGF-1) rather than the **GPCR-linked** TSH receptor.
- It is primarily associated with **cellular proliferation** and oncogenic signaling (e.g., in thyroid cancer) rather than the acute physiological production of **T3 and T4**.
*TGF-beta receptor-SMAD pathway regulating gene transcription*
- The **SMAD pathway** is utilized by the **Transforming Growth Factor-beta (TGF-̢)** superfamily to regulate cell growth and differentiation.
- It does not mediate the stimulatory effects of **TSH receptor antibodies** or the metabolic hyperactivity seen in **Graves' disease**.
*Gi protein inhibition of adenylyl cyclase decreasing cAMP*
- Activation of **Gi protein** leads to a **reduction** in cAMP levels, which would inhibit thyroid function rather than cause hyperthyroidism.
- This is the opposite of the physiological effect of **TSH receptor agonists**, which must increase cAMP to stimulate the **thyroid follicular cells**.
Question 9: A 3-year-old boy presents with severe dehydration, chronic watery diarrhea, and failure to thrive. Laboratory studies reveal hypochlorhydria and elevated vasoactive intestinal peptide (VIP) levels. Imaging reveals a pancreatic mass consistent with VIPoma. The excessive VIP secretion causes persistent activation of which signal transduction pathway in intestinal epithelial cells to produce the diarrhea?
A. JAK-STAT pathway activation by cytokine receptors
B. Gi protein inhibition of adenylyl cyclase reducing cAMP
C. Gq protein activation of phospholipase C producing IP3
D. Receptor tyrosine kinase activation of PI3K/Akt pathway
E. Gs protein activation of adenylyl cyclase increasing cAMP (Correct Answer)
Explanation: ***Gs protein activation of adenylyl cyclase increasing cAMP***
- **Vasoactive Intestinal Peptide (VIP)** binds to its G protein-coupled receptor leading to the activation of **Gs proteins**, which stimulate **adenylyl cyclase**.
- Increased **cAMP** levels activate **Protein Kinase A (PKA)**, which phosphorylates **CFTR channels**, causing massive chloride and water secretion into the intestinal lumen.
*Gi protein inhibition of adenylyl cyclase reducing cAMP*
- **Gi proteins** function to inhibit adenylyl cyclase, which would lead to a **decrease** in cAMP levels rather than an increase.
- This pathway is typically associated with hormones like **somatostatin**, which actually works to counteract the effects of VIP.
*Gq protein activation of phospholipase C producing IP3*
- The **Gq pathway** activates **Phospholipase C (PLC)** to produce **IP3** and **DAG**, which is characteristic of hormones like **oxytocin** or **histamine (H1)**.
- While this pathway increases intracellular **calcium**, it is not the mechanism used by **VIP** to induce secretory diarrhea.
*Receptor tyrosine kinase activation of PI3K/Akt pathway*
- This pathway is primarily involved in **cell growth**, **survival**, and **metabolism**, often activated by **insulin** or **growth factors**.
- It does not regulate the massive **electrolyte and water secretion** seen in the clinical presentation of a **VIPoma**.
*JAK-STAT pathway activation by cytokine receptors*
- The **JAK-STAT pathway** is utilized by **cytokines** and certain hormones like **prolactin** or **growth hormone** for gene transcription.
- It plays no role in the acute activation of intestinal **ion channels** that results in chronic watery diarrhea.
Question 10: A 45-year-old woman with type 2 diabetes mellitus presents for routine follow-up. Her physician prescribes exenatide, a GLP-1 receptor agonist, to improve glycemic control. The drug increases insulin secretion and decreases glucagon release in a glucose-dependent manner. Through which signal transduction mechanism does GLP-1 receptor activation primarily lead to insulin secretion in pancreatic beta cells?
A. Opening of ligand-gated calcium channels
B. Activation of adenylyl cyclase leading to increased cAMP levels (Correct Answer)
C. Activation of phospholipase C leading to IP3 and DAG production
D. Direct activation of protein kinase C
E. Activation of receptor tyrosine kinase leading to MAP kinase cascade
Explanation: ***Activation of adenylyl cyclase leading to increased cAMP levels***
- The GLP-1 receptor is a **G protein-coupled receptor (GPCR)** coupled to the **Gs subunit**, which stimulates **adenylyl cyclase** upon activation.
- Increased **cAMP** levels enhance insulin secretion by activating **Protein Kinase A (PKA)** and **Epac2**, which promote the exocytosis of insulin granules.
*Activation of phospholipase C leading to IP3 and DAG production*
- This signal transduction pathway is associated with **Gq-coupled receptors**, such as the **M3 muscarinic receptor** or the GPR40 receptor on beta cells.
- While it increases intracellular calcium, it is not the primary mechanism by which **GLP-1 receptor agonists** like exenatide exert their effect.
*Opening of ligand-gated calcium channels*
- Insulin release involves **voltage-gated calcium channels** that open in response to membrane **depolarization**, not ligand-gated channels.
- GLP-1 modulates the release of insulin but does not act as a direct ligand for opening primary calcium channels.
*Activation of receptor tyrosine kinase leading to MAP kinase cascade*
- **Receptor tyrosine kinases** are typically used by growth factors and **insulin** itself at its target tissues, rather than the GLP-1 receptor.
- The GLP-1 receptor belongs to the **glucagon receptor family** of GPCRs, which prioritize **cyclic nucleotide** signaling over MAP kinase pathways.
*Direct activation of protein kinase C*
- **Protein Kinase C (PKC)** is typically activated downstream of **diacylglycerol (DAG)** production in the Gq pathway.
- GLP-1 primarily signals through **Protein Kinase A (PKA)** via the stimulatory Gs/cAMP pathway rather than direct PKC activation.
